PE20131463A1 - Piperidino-dihidrotienopirimidinas sustituidas - Google Patents
Piperidino-dihidrotienopirimidinas sustituidasInfo
- Publication number
- PE20131463A1 PE20131463A1 PE2013001391A PE2013001391A PE20131463A1 PE 20131463 A1 PE20131463 A1 PE 20131463A1 PE 2013001391 A PE2013001391 A PE 2013001391A PE 2013001391 A PE2013001391 A PE 2013001391A PE 20131463 A1 PE20131463 A1 PE 20131463A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidine
- pyrimidin
- piperidin
- chlorophenyl
- dihydro
- Prior art date
Links
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 PYRIMIDIN-4 -YLAMINE -3-METHYLBUTAN-1-OL Chemical compound 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A PIPERIDINO-DIHIDROTIENOPIRIMIDINAS SUSTITUIDAS DE FORMULA 1, DONDE X ES SO; R1 ES H Y ALQUILO C1-C6; R2 ES UN CICLOALQUILO C3-C10, PIPERIDINA, TETRAHIDROPIRANO ENTRE OTROS; R3 ES UN NAFTALENO, FENILO ENTRE OTROS; R4 ES H, CN, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (2)-2- 2- 4- 4-CLOROFENIL)-PIPERIDIN-1-IL -5-OXO-6,7-DIHIDRO-5H-5?4-TIENO 3,2-d PIRIMIDIN-4-ILAMINO -3-METILBUTAN-1-OL, 1- 2- 4- 4-CLOROFENIL -PIPERIDIN-1-IL -5-OXO-6,7-DIHIDRO-5H-5?4-TIENO 3,2-d PIRIMIDIN-4-ILAMINO -CICLOPROPIL -METANOL, R -2- 2- 4- 4-CLOROFENIL)-PIPERIDIN-1-IL -5-OXO-6,7-DIHIDRO-5H-5?4-TIENO 3,2-d PIRIMIDIN-4-ILAMINO -PENTAN-1-OL. REFERIDA TAMBIEN A UNA FORMULACION FARMACEUTICA. DICHO COMPUESTO ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DE LAS VIAS RESPIRATORIAS ENTRE OTRAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118901 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131463A1 true PE20131463A1 (es) | 2013-12-23 |
Family
ID=39154006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001796A PE20091386A1 (es) | 2007-10-19 | 2008-10-17 | Piperidino-dihidrotienopirimidinas sustituidas |
| PE2013001391A PE20131463A1 (es) | 2007-10-19 | 2008-10-17 | Piperidino-dihidrotienopirimidinas sustituidas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001796A PE20091386A1 (es) | 2007-10-19 | 2008-10-17 | Piperidino-dihidrotienopirimidinas sustituidas |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8754073B2 (es) |
| EP (3) | EP2380891B1 (es) |
| JP (2) | JP5150728B2 (es) |
| KR (1) | KR101548975B1 (es) |
| CN (2) | CN101827852B (es) |
| AR (1) | AR069075A1 (es) |
| AT (1) | ATE542825T1 (es) |
| AU (1) | AU2008313660B2 (es) |
| BR (1) | BRPI0818006B8 (es) |
| CA (1) | CA2705414C (es) |
| CL (1) | CL2008003096A1 (es) |
| CY (2) | CY1112703T1 (es) |
| DK (2) | DK2215092T3 (es) |
| EA (1) | EA019480B1 (es) |
| EC (1) | ECSP10010156A (es) |
| ES (2) | ES2381452T3 (es) |
| HR (2) | HRP20120334T1 (es) |
| MA (1) | MA31845B1 (es) |
| ME (1) | ME01330B (es) |
| MX (1) | MX2010004026A (es) |
| MY (1) | MY153979A (es) |
| NZ (1) | NZ585346A (es) |
| PE (2) | PE20091386A1 (es) |
| PL (2) | PL2610258T3 (es) |
| PT (2) | PT2215092E (es) |
| RS (1) | RS52271B (es) |
| SI (2) | SI2610258T1 (es) |
| TN (1) | TN2010000175A1 (es) |
| TW (1) | TWI421077B (es) |
| UA (1) | UA99309C2 (es) |
| UY (1) | UY31405A1 (es) |
| WO (1) | WO2009050248A1 (es) |
| ZA (1) | ZA201001683B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| KR20100095528A (ko) | 2007-10-18 | 2010-08-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체 |
| MX2010003346A (es) | 2007-10-19 | 2010-04-09 | Boehringer Ingelheim Int | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. |
| WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
| WO2009050248A1 (de) * | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituierte piperidino-dihydrothienopyrimidine |
| EP2400962B1 (de) | 2009-02-27 | 2017-11-08 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| EP2555773A1 (de) | 2010-04-08 | 2013-02-13 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
| WO2011124525A1 (de) | 2010-04-08 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US9499519B2 (en) | 2012-12-26 | 2016-11-22 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| EP2951173B1 (en) | 2013-02-04 | 2017-05-17 | Grünenthal GmbH | Novel substituted condensed pyrimidine compounds |
| WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| CN104892720B (zh) * | 2014-03-07 | 2016-10-26 | 华东师范大学 | 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用 |
| WO2018003962A1 (ja) * | 2016-06-30 | 2018-01-04 | 国立研究開発法人理化学研究所 | 新規化合物又はその薬理学的に許容される塩 |
| JP7216719B2 (ja) * | 2017-09-20 | 2023-02-01 | ユニオン・セラピューティクス・アクティエセルスカブ | 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用 |
| RS67241B1 (sr) | 2017-10-23 | 2025-10-31 | Boehringer Ingelheim Int | Nova kombinacija aktivnih agensa za lečenje progresivnih fibroznih intersticijalnih bolesti pluća (pf-ild) |
| CN111727191B (zh) | 2017-12-15 | 2024-01-05 | 联合疗法公司 | 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
| CN111712502B (zh) | 2017-12-15 | 2023-10-27 | 联合疗法公司 | 取代的氮杂环丁烷二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
| CN111712503B (zh) * | 2017-12-15 | 2024-04-09 | 联合疗法公司 | 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
| WO2020048827A1 (en) * | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| ES3041145T3 (en) | 2021-12-09 | 2025-11-07 | Boehringer Ingelheim Int | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases |
| JP2024541514A (ja) | 2021-12-09 | 2024-11-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 進行性線維化を伴う間質性肺疾患を処置するための、新たな治療的組合せ |
| KR20250018499A (ko) * | 2022-06-02 | 2025-02-06 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Pde4b 억제제 및 이의 용도 |
| CN117247395A (zh) * | 2022-06-16 | 2023-12-19 | 武汉人福创新药物研发中心有限公司 | Pde4b抑制剂 |
| CN115040503B (zh) * | 2022-07-26 | 2023-10-10 | 云南民族大学 | 螺环二烯酮型木脂素类化合物在制药中的应用 |
| JP2025528779A (ja) * | 2022-08-09 | 2025-09-02 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｐｄｅ４ｂ阻害剤及びその用途 |
| CN119947728A (zh) | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
| CN119698422A (zh) * | 2022-09-29 | 2025-03-25 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物、其制备方法及其在医药上的应用 |
| CN118871444A (zh) * | 2023-02-28 | 2024-10-29 | 上海翊石医药科技有限公司 | 二氢噻吩并嘧啶衍生物的制备方法和用途 |
| WO2024208225A1 (zh) * | 2023-04-03 | 2024-10-10 | 上海壹迪生物技术有限公司 | 二氢噻吩并嘧啶类化合物、其制备方法和应用 |
| CN120752243A (zh) * | 2023-04-13 | 2025-10-03 | 上海壹迪生物技术有限公司 | 取代的二氢噻吩并嘧啶类化合物、其制备方法和应用 |
| CN116925099B (zh) * | 2023-07-21 | 2025-06-03 | 厦门大学 | 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物 |
| WO2025038987A2 (en) * | 2023-08-17 | 2025-02-20 | Katalytic Therapeutics, Inc. | Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications |
| WO2025067168A1 (zh) * | 2023-09-25 | 2025-04-03 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物及其制备方法和用途 |
| WO2025161532A1 (zh) * | 2024-02-01 | 2025-08-07 | 艾派克斯生物科技有限公司 | Pde4b抑制剂及其药物组合物和用途 |
| WO2025162431A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | 一种pde4b抑制剂化合物的口服药物组合物及其制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470336A1 (de) * | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
| NL122810C (es) | 1963-06-17 | |||
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| BE663693A (es) | 1965-03-31 | |||
| DE1940572A1 (de) | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| DE2032687A1 (en) | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
| US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| FR2082496A5 (es) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
| DE2121950A1 (en) | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
| DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US5187168A (en) * | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| US5491201A (en) | 1992-02-06 | 1996-02-13 | The Dow Chemical Company | Mesogenic cyclic imino ether-containing compositions and polymerization products thereof |
| JPH07330777A (ja) | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 |
| JPH09301958A (ja) | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| AU2001229501A1 (en) | 2000-01-24 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of inducible nitric oxide synthase expression |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| ES2228965T3 (es) | 2000-10-12 | 2005-04-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion y su uso para la produccion de un medicamento. |
| DE10064994A1 (de) * | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
| EP1401840A4 (en) | 2001-04-30 | 2007-05-16 | Bayer Corp | NEW 4-AMINO-5,6-SUBSTITUTED THIOPHENO 2,3 D | PYRIMIDINE |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| EP1401445B1 (de) | 2001-06-22 | 2006-08-23 | Boehringer Ingelheim Pharma GmbH & Co.KG | Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels |
| US6587548B2 (en) * | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
| WO2003055890A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| CA2472619A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Corporation | Fused pyrimidine derivates as rho-kinase inhibitors |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| DK1620437T3 (da) | 2003-04-29 | 2009-08-24 | Pfizer Ltd | 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension |
| EP1654385A4 (en) | 2003-05-16 | 2006-11-08 | Wisconsin Alumni Res Found | PROCESS FOR THE INSULATION AND CLONING OF HIGH-MOLECULAR POLYNUCLEOTIDE MOLECULES FROM THE ENVIRONMENT |
| JP2005003345A (ja) | 2003-05-21 | 2005-01-06 | Showa Denko Kk | 換気兼熱交換装置および空調システム |
| JP4733043B2 (ja) * | 2003-10-02 | 2011-07-27 | マーテック バイオサイエンシーズ コーポレーション | 改変された量の塩化物およびカリウムを使用した微細藻類における高レベルのｄｈａの産生法 |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| ES2340855T3 (es) | 2003-12-23 | 2010-06-10 | Serodus As | Modulares de receptores 5-ht perifericos. |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| AU2006245770A1 (en) | 2005-05-11 | 2006-11-16 | Nycomed Gmbh | Combination of the PDE4 inhibitor roflumilast and a tetrahydrobiopterin derivative |
| EP1874781B9 (de) | 2006-04-19 | 2010-09-08 | Boehringer Ingelheim International GmbH | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
| EP1847543A1 (de) * | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| JP5389013B2 (ja) * | 2007-04-20 | 2014-01-15 | グラクソ グループ リミテッド | 抗菌剤としての三環式含窒素化合物 |
| KR20100095528A (ko) * | 2007-10-18 | 2010-08-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체 |
| WO2009050248A1 (de) * | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituierte piperidino-dihydrothienopyrimidine |
| CN101903365B (zh) | 2007-10-19 | 2014-02-05 | 默沙东公司 | 用于抑制ksp驱动蛋白活性的螺缩合的1,3,4-噻二唑衍生物 |
| WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
| WO2009053268A1 (de) | 2007-10-19 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Neue phenyl-substituierte piperazino-dihydrothienopyrimidine |
| FR2922550B1 (fr) * | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
| MX2010003346A (es) * | 2007-10-19 | 2010-04-09 | Boehringer Ingelheim Int | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. |
| JP2011500673A (ja) | 2007-10-19 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | 代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体 |
| EP2400962B1 (de) * | 2009-02-27 | 2017-11-08 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| WO2010097332A1 (de) | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| US20130059866A1 (en) * | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
-
2008
- 2008-10-16 WO PCT/EP2008/063999 patent/WO2009050248A1/de not_active Ceased
- 2008-10-16 ES ES08839793T patent/ES2381452T3/es active Active
- 2008-10-16 EP EP11174754.9A patent/EP2380891B1/de active Active
- 2008-10-16 CN CN200880112254.5A patent/CN101827852B/zh active Active
- 2008-10-16 HR HRP20120334AT patent/HRP20120334T1/hr unknown
- 2008-10-16 UA UAA201005780A patent/UA99309C2/ru unknown
- 2008-10-16 SI SI200831314T patent/SI2610258T1/sl unknown
- 2008-10-16 US US12/738,344 patent/US8754073B2/en active Active
- 2008-10-16 JP JP2010529389A patent/JP5150728B2/ja active Active
- 2008-10-16 PL PL13154790T patent/PL2610258T3/pl unknown
- 2008-10-16 PT PT08839793T patent/PT2215092E/pt unknown
- 2008-10-16 SI SI200830579T patent/SI2215092T1/sl unknown
- 2008-10-16 BR BRPI0818006A patent/BRPI0818006B8/pt active IP Right Grant
- 2008-10-16 AT AT08839793T patent/ATE542825T1/de active
- 2008-10-16 ES ES13154790.3T patent/ES2524910T3/es active Active
- 2008-10-16 EA EA201000609A patent/EA019480B1/ru not_active IP Right Cessation
- 2008-10-16 NZ NZ585346A patent/NZ585346A/en unknown
- 2008-10-16 CA CA2705414A patent/CA2705414C/en active Active
- 2008-10-16 EP EP13154790.3A patent/EP2610258B1/de active Active
- 2008-10-16 EP EP08839793A patent/EP2215092B1/de active Active
- 2008-10-16 KR KR1020107010905A patent/KR101548975B1/ko active Active
- 2008-10-16 PL PL08839793T patent/PL2215092T3/pl unknown
- 2008-10-16 RS RS20120144A patent/RS52271B/sr unknown
- 2008-10-16 AU AU2008313660A patent/AU2008313660B2/en active Active
- 2008-10-16 MY MYPI2010001693A patent/MY153979A/en unknown
- 2008-10-16 DK DK08839793.0T patent/DK2215092T3/da active
- 2008-10-16 CN CN201410312258.5A patent/CN104069112A/zh active Pending
- 2008-10-16 DK DK13154790.3T patent/DK2610258T3/da active
- 2008-10-16 PT PT131547903T patent/PT2610258E/pt unknown
- 2008-10-16 ME MEP-2012-26A patent/ME01330B/me unknown
- 2008-10-16 MX MX2010004026A patent/MX2010004026A/es active IP Right Grant
- 2008-10-17 CL CL2008003096A patent/CL2008003096A1/es unknown
- 2008-10-17 TW TW097139983A patent/TWI421077B/zh active
- 2008-10-17 PE PE2008001796A patent/PE20091386A1/es not_active Application Discontinuation
- 2008-10-17 PE PE2013001391A patent/PE20131463A1/es not_active Application Discontinuation
- 2008-10-17 UY UY31405A patent/UY31405A1/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104560A patent/AR069075A1/es active IP Right Grant
-
2010
- 2010-03-09 ZA ZA201001683A patent/ZA201001683B/xx unknown
- 2010-04-16 TN TN2010000175A patent/TN2010000175A1/fr unknown
- 2010-05-05 EC EC2010010156A patent/ECSP10010156A/es unknown
- 2010-05-12 MA MA32832A patent/MA31845B1/fr unknown
-
2012
- 2012-04-23 CY CY20121100378T patent/CY1112703T1/el unknown
- 2012-12-03 JP JP2012264647A patent/JP5615889B2/ja active Active
-
2014
- 2014-11-26 HR HRP20141153AT patent/HRP20141153T1/hr unknown
- 2014-11-26 CY CY20141100984T patent/CY1115858T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131463A1 (es) | Piperidino-dihidrotienopirimidinas sustituidas | |
| ES2572148T3 (es) | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados | |
| TNSN08407A1 (en) | Organic compounds | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| NO20084783L (no) | Syntese av acylaminoalkenylenamider nyttige som substans P antagonister | |
| PE20140011A1 (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| CY1107168T1 (el) | Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| TW200745070A (en) | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and their use | |
| ATE540932T1 (de) | Hydantoin-derivate als antibakterielle wirkstoffe | |
| TW200745069A (en) | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use | |
| PE20020476A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
| NO20083434L (no) | Benzamid- og heteroarenderivater | |
| NO20054852L (no) | GFAT inhibitorer | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| EA200400981A1 (ru) | Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз | |
| SG10201806714PA (en) | C7-fluoro substituted tetracycline compounds | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| GB0607954D0 (en) | Organic compounds | |
| ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
| ZA200907956B (en) | Novel carbamoyloxy arylalkanoyl arylpiperazine compound,pharmaceutical compositions comprising the compound and method for treating pain,anxiety and depression by administering the compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |